Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Deffered Revenue: 2013-2025

Historic Non-Current Deffered Revenue for Ocular Therapeutix (OCUL) over the last 10 years, with Sep 2025 value amounting to $14.0 million.

  • Ocular Therapeutix's Non-Current Deffered Revenue changed negligibly% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $14.0 million for FY2024, which is 0.96% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Non-Current Deffered Revenue of $14.0 million as of Q3 2025, which was down 0.00% from $14.0 million recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Non-Current Deffered Revenue high stood at $14.3 million for Q2 2023, and its period low was $12.0 million during Q1 2021.
  • Its 3-year average for Non-Current Deffered Revenue is $14.0 million, with a median of $14.0 million in 2025.
  • Per our database at Business Quant, Ocular Therapeutix's Non-Current Deffered Revenue increased by 12.78% in 2022 and then dropped by 1.78% in 2024.
  • Ocular Therapeutix's Non-Current Deffered Revenue (Quarterly) stood at $13.0 million in 2021, then grew by 2.98% to $13.4 million in 2022, then grew by 5.59% to $14.1 million in 2023, then declined by 0.96% to $14.0 million in 2024, then remained steady at $14.0 million in 2025.
  • Its last three reported values are $14.0 million in Q3 2025, $14.0 million for Q2 2025, and $14.0 million during Q1 2025.